Captor Therapeutics Spolka Akcyjna (WSE:CTX)

Market Cap	453.00M +110.1%
Revenue (ttm)	2.38M -82.9%
Net Income	-42.65M
EPS	-7.71
Shares Out	6.35M
PE Ratio	n/a
Forward PE	102.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,337
Open	71.10
Previous Close	71.50
Day's Range	70.60 - 71.90
52-Week Range	33.00 - 89.20
Beta	0.55
Analysts	Strong Buy
Price Target	86.83 (+21.78%)
Earnings Date	Sep 15, 2026

About WSE:CTX

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that utilizes the Optigrade drug discovery platform to overcome the limitations of inhibitors and antibody drugs by destroying disease-causing proteins that are resistant to available therapeutics. It develops viadrudomide, which is in a Phase 1 clinical trial for hepatocellular carcinoma (HCC), lung cancer, and rare cancers; vratito...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 82
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CTX

Financial Performance

In 2025, WSE:CTX's revenue was 4.66 million, a decrease of -70.55% compared to the previous year's 15.83 million. Losses were -42.00 million, 9.29% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for CTX stock is "Strong Buy." The 12-month stock price target is zł 86.83, which is an increase of 21.78% from the latest price.

Price Target

zł 86.83

(21.78% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 4, 2026

Data Sources Report a data error